[go: up one dir, main page]

ATE497978T1 - Pharmazeutische zusammensetzungen von antikörpern von viruserkrankungen - Google Patents

Pharmazeutische zusammensetzungen von antikörpern von viruserkrankungen

Info

Publication number
ATE497978T1
ATE497978T1 AT08447031T AT08447031T ATE497978T1 AT E497978 T1 ATE497978 T1 AT E497978T1 AT 08447031 T AT08447031 T AT 08447031T AT 08447031 T AT08447031 T AT 08447031T AT E497978 T1 ATE497978 T1 AT E497978T1
Authority
AT
Austria
Prior art keywords
antibodies
pharmaceutical compositions
virus diseases
interferon gamma
peptide sequence
Prior art date
Application number
AT08447031T
Other languages
English (en)
Inventor
Michel Thiry
Andrey Marttyushev-Poklad
Original Assignee
Theranor Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theranor Sprl filed Critical Theranor Sprl
Application granted granted Critical
Publication of ATE497978T1 publication Critical patent/ATE497978T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08447031T 2008-06-27 2008-06-27 Pharmazeutische zusammensetzungen von antikörpern von viruserkrankungen ATE497978T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08447031A EP2138513B1 (de) 2008-06-27 2008-06-27 Pharmazeutische Zusammensetzungen von Antikörpern von Viruserkrankungen

Publications (1)

Publication Number Publication Date
ATE497978T1 true ATE497978T1 (de) 2011-02-15

Family

ID=40032474

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08447031T ATE497978T1 (de) 2008-06-27 2008-06-27 Pharmazeutische zusammensetzungen von antikörpern von viruserkrankungen

Country Status (8)

Country Link
US (1) US9409991B2 (de)
EP (1) EP2138513B1 (de)
CN (1) CN102216330B (de)
AT (1) ATE497978T1 (de)
CA (1) CA2729226C (de)
DE (1) DE602008004898D1 (de)
ES (1) ES2360334T3 (de)
WO (1) WO2009155670A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104136454A (zh) * 2011-10-12 2014-11-05 阿尔法-O肽股份公司 作为针对诺如病毒感染的疫苗的自装配肽纳米粒
US10574712B2 (en) 2016-02-19 2020-02-25 International Business Machines Corporation Provisioning conference rooms
CN117242088A (zh) 2020-08-05 2023-12-15 辛德凯因股份有限公司 Il10受体结合分子和使用方法
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
WO2022031890A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr2 binding molecules and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2169849A1 (en) * 1993-08-20 1995-03-02 Sidney Pestka Accessory factor function for interferon gamma and its receptor
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US7115264B2 (en) 2001-11-05 2006-10-03 Inhibitex Monoclonal antibodies to the fibronectin binding protein and method of use in treating or preventing infections
WO2003092615A2 (en) 2002-05-01 2003-11-13 Beth Israel Deaconess Medical Center Use of anti-cd1 antibodies for the modulation of immune responses
JP2004016021A (ja) * 2002-06-12 2004-01-22 Japan Science & Technology Corp 抗体および阻害剤並びにそれを用いた形質転換方法および形質転換キット
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
AU2003302235A1 (en) 2002-12-03 2004-06-23 Sloan-Kettering Institute For Cancer Research Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
PL378879A1 (pl) * 2002-12-30 2006-05-29 Amgen Inc. Terapia skojarzona z czynnikami kostymulującymi
US20050136103A1 (en) 2003-09-17 2005-06-23 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
CA2587676A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
AR051836A1 (es) * 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos
DK1848744T3 (da) * 2005-01-27 2012-03-19 Novimmune Sa Humane anti-interferon-gamma-antistoffer og fremgangsmåder til anvendelse heraf
ES2435775T3 (es) * 2005-10-27 2013-12-23 Janssen Biotech, Inc. Moduladores de receptor tipo Toll 3, procedimientos y usos
US20090068684A1 (en) * 2007-03-26 2009-03-12 Cell Signaling Technology, Inc. Serine and threoninephosphorylation sites

Also Published As

Publication number Publication date
WO2009155670A8 (en) 2011-02-17
EP2138513B1 (de) 2011-02-09
WO2009155670A3 (en) 2010-04-01
US9409991B2 (en) 2016-08-09
CN102216330A (zh) 2011-10-12
ES2360334T3 (es) 2011-06-03
US20110177081A1 (en) 2011-07-21
CN102216330B (zh) 2014-04-16
DE602008004898D1 (de) 2011-03-24
CA2729226C (en) 2016-08-16
CA2729226A1 (en) 2009-12-30
WO2009155670A2 (en) 2009-12-30
EP2138513A1 (de) 2009-12-30

Similar Documents

Publication Publication Date Title
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
BR112012011100A2 (pt) compostos inibidores do vírus da hepatite, composição e uso dos mesmos
CL2009000305A1 (es) Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
CL2009002206A1 (es) Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
MX2010001733A (es) Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.
SV2005001920A (es) " compuestos nucleosidos para el tratamiento de infecciones virales "
CL2008001005A1 (es) Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv.
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
BRPI0906710B8 (pt) peptídeo derivado de pres modificado hidrofóbico de vírus da hepatite b (hbv) , peptídeo e composição farmacêutica
ATE554789T1 (de) Neues hundeinfluenza-virus und imfpstoff hierfür
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
BR122021002201A8 (pt) Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
CY1106207T1 (el) Αντιιικα παραγωγα νουκλεοζιτων
EA200802247A1 (ru) Схема дозирования кладрибина для лечения рассеянного склероза
BR112014004860A2 (pt) composições de anticorpo contra vírus da influenza
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
BR112013002729A2 (pt) inibidores de vírus de hepatite c
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
NI201100076A (es) Péptidos antivirales terapéuticos.
WO2009026465A3 (en) Composition and methods of making and using influenza proteins
DK2186830T3 (da) Polyethylenglycol modificeret interferon alpha 2B og fremstillingsfremgangsmåde og applikationer deraf
UY30778A1 (es) Compuestos de 5,6-dihidro-1h-piridin-2-ona
BR112013028679A2 (pt) inibidores do vírus da hepatite c
UY31685A (es) Compuestos antivirales, composiciones y metodos para usarlos
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties